Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 1/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 16/20 | 0.45 |
| ▸ | PI4KA | P42356 | 15/20 | 0.45 |
| ▸ | PI4KB | Q9UBF8 | 15/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 14/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 13/20 | 0.45 |
| ▸ | PIK3CB | P42338 | 11/20 | 0.45 |
| ▸ | AXL | P30530 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | PIP5K1C | O60331 | 5/20 | 0.42 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.41 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.41 |
| ▸ | AKT1 | P31749 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10070633 | 0.90 | PI4KA (0.46) | PIK3CAPI4KAPI4KBPIK3CDPIK3CG | |
| SCHEMBL15131809 | 0.87 | PIK3CA (0.43) | PIK3CAPI4KAPI4KBPIK3CDPIK3CG | |
| SCHEMBL15131802 | 0.80 | PRKDC (0.48) | PIK3CBMTOR | |
| SCHEMBL807985 | 0.79 | PIK3CA (0.45) | PIK3CAPI4KAPI4KBPIK3CDPIK3CG | |
| SCHEMBL807819 | 0.78 | PIK3CA (0.43) | PIK3CAPI4KBPIK3CDPIK3CGPIK3CB | |
| SCHEMBL807817 | 0.78 | PI4KA (0.52) | PIK3CAPI4KAPI4KBPIK3CDPIK3CG | |
| SCHEMBL807826 | 0.76 | PI4KA (0.45) | PIK3CAPI4KAPI4KBPIK3CDPIK3CG | |
| SCHEMBL15131799 | 0.74 | PI4KA (0.48) | PIK3CAPI4KAPI4KBPIK3CDPIK3CG | |
| SCHEMBL15131807 | 0.70 | PRKDC (0.52) | PIK3CBMTOR | |
| SCHEMBL10070628 | 0.67 | PIK3CA (0.46) | PIK3CAPI4KBPIK3CDPIK3CGPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181264-B2 | Fused heteroaryls and their uses | HUTCHISON MEDIPHARMA LIMITED (CN) | 2015-11-10 | — | — | US | disclosed |
| US-9181264-B2 | Fused heteroaryls and their uses | HUTCHISON MEDIPHARMA LIMITED (CN) | 2015-11-10 | — | — | US | disclosed |
| US-20130190307-A1 | FUSED HETEROARYLS AND THEIR USES | HUTCHISON MEDIPHARMA LIMITED (CN) | 2013-07-25 | — | — | US | disclosed |
| US-20130190307-A1 | FUSED HETEROARYLS AND THEIR USES | HUTCHISON MEDIPHARMA LIMITED (CN) | 2013-07-25 | — | — | US | disclosed |
| WO-2012034526-A1 | FUSED HETEROARYLS AND THEIR USES | HUTCHISON MEDIPHARMA LIMITED (CN) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190307-A1 | FUSED HETEROARYLS AND THEIR USES | FARS2, TIAL1, DHFR | MET 1020/4885PIK3CA 1962/4885PI4KA 2058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.